An overview of drug-induced acute kidney injury

Critical Care Medicine

Volumn 36, Issue SUPPL. 4, 2008, Pages

  Pannu, Neesh ^a   Nadim, Mitra K ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Acute kidney injury; Acute tubular necrosis; Nephrotoxic drugs

Indexed keywords

ACICLOVIR; ALPHA TOCOPHEROL; AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; ASCORBIC ACID; CALCINEURIN INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DEFEROXAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GENTAMICIN; GOLD; HYDRALAZINE; HYPERTENSIVE AGENT; IMMUNOGLOBULIN; INDINAVIR; ITRACONAZOLE; NEOMYCIN; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PENICILLIN DERIVATIVE; PREDNISONE; PROBUCOL; SELENIUM; STREPTOMYCIN; SULINDAC; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN; VORICONAZOLE;

ACUTE KIDNEY TUBULE NECROSIS; BACTERIAL INFECTION; CREATININE BLOOD LEVEL; CRITICALLY ILL PATIENT; DRUG HALF LIFE; FUNGEMIA; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; HUMAN; HYPOKALEMIA; INTERSTITIAL NEPHRITIS; KIDNEY BLOOD FLOW; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY ISCHEMIA; KIDNEY PAPILLA NECROSIS; NEPHROSIS; NEPHROTOXICITY; NONHUMAN; OBSTRUCTIVE UROPATHY; OTOTOXICITY; PRIORITY JOURNAL; RENAL VASCULITIS; REVIEW; SIDE EFFECT;

EID: 41649087623     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCM.0b013e318168e375     Document Type: Review

References (107)

1. Uchino S: The epidemiology of acute renal failure in the world. Curr Opin Crit Care 2006; 12:538-543
2. Chertow GM, Burdick E, Honour M, et al: Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005; 16:3365-3370
3. Uchino S, Kellum JA, Bellomo R, et al: Acute renal failure in critically ill patients: A multinational, multicenter study. JAMA 2005; 294:813-818
4. Mehta RL, Pascual MT, Soroko S, et al: Spectrum of acute renal failure in the intensive care unit: The PICARD experience. Kidney Int 2004; 66:1613-1621
5. Humes HD: Aminoglycoside nephrotoxicity. Kidney Int 1988; 33:900-911
6. Rybak MJ, Abate BJ, Kang SL, et al: Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 1999; 43:1549-1555
7. Mingeot-Leclercq MP, Tulkens PM: Aminoglycosides: Nephrotoxicity. Antimicrob Agents Chemother 1999; 43:1003-1012
8. Swan SK: Aminoglycoside nephrotoxicity. Semin Nephrol 1997; 17:27-33
9. Bennett WM, Wood CA, Houghton DC, et al: Modification of experimental aminoglycoside nephrotoxicity. Am J Kidney Dis 1986; 8:292-296
10. Matzke GR, Lucarotti RL, Shapiro HS: Controlled comparison of gentamicin and tobramycin nephrotoxicity. Am J Nephrol 1983; 3:11-17
11. Smith CR, Lipsky JJ, Laskin OL, et al: Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med 1980; 302:1106-1109
12. Meyer RD: Risk factors and comparisons of clinical nephrotoxicity of aminoglycosides. Am J Med 1986; 80:119-125
13. Olbricht CJ, Fink M, Gutjahr E: Alterations in lysosomal enzymes of the proximal tubule in gentamicin nephrotoxicity. Kidney Int 1991; 39:639-646
14. Ward DT, McLarnon SJ, Riccardi D: Aminoglycosides increase intracellular calcium levels and ERK activity in proximal tubular OK cells expressing the extracellular calcium-sensing receptor. J Am Soc Nephrol 2002; 13:1481-1489
15. Ward DT, Maldonado-Perez D, Hollins L, et al: Aminoglycosides induce acute cell signaling and chronic cell death in renal cells that express the calcium-sensing receptor. J Am Soc Nephrol 2005; 16:1236-1244
16. Bertino JS Jr, Booker LA, Franck PA, et al: Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis 1993; 167:173-179
17. Etzel JV, Nafziger AN, Bertino JS Jr: Variation in the pharmacokinetics of gentamicin and tobramycin in patients with pleural effusions and hypoalbuminemia. Antimicrob Agents Chemother 1992; 36:679-681
18. Moore RD, Smith CR, Lipsky JJ, et al: Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med 1984; 100:352-357
19. Sawyers CL, Moore RD, Lerner SA, et al: A model for predicting nephrotoxicity in patients treated with aminoglycosides. J Infect Dis 1986; 153:1062-1068
20. Zarowitz BJ, Pilla AM, Popovich J Jr: Expanded gentamicin volume of distribution in patients with indicators of malnutrition. Clin Pharm 1990; 9:40-44
21. Humes HD, Sastrasinh M, Weinberg JM: Calcium is a competitive inhibitor of gentamicin-renal membrane binding interactions and dietary calcium supplementation protects against gentamicin nephrotoxicity. J Clin Invest 1984; 73:134-147
22. Bennett WM, Elliott WC, Houghton DC, et al: Reduction of experimental gentamicin nephrotoxicity in rats by dietary calcium loading. Antimicrob Agents Chemother 1982; 22:508-512
23. Perez de la Cruz MJ, Cadorniga R, Ochoa MC, et al: Chronopharmacokinetics and calcium in the prevention of gentamicin-induced nephrotoxicity in rabbits. Biopharm Drug Dispos 1998; 19:407-412
24. Vlasic-Matas J, Rumboldt Z, Karelovic D: Renoprotective role of nifedipine during gentamicin therapy: Randomized controlled trial. Croat Med J 2000; 41:417-422
25. Hayashi T, Watanabe Y, Kumano K, et al: Protective effect of piperacillin against nephrotoxicity of cephaloridine and gentamicin in animals. Antimicrob Agents Chemother 1988; 32:912-918
26. Bloch R, Luft FC, Rankin LI, et al: Protection from gentamicin nephrotoxicity by cephalothin and carbenicillin. Antimicrob Agents Chemother 1979; 15:46-49
27. Beauchamp D, Theriault G, Grenier L, et al: Ceftriaxone protects against tobramycin nephrotoxicity. Antimicrob Agents Chemother 1994; 38:750-756
28. Abdel-Naim AB, Abdel-Wahab MH, Attia FF: Protective effects of vitamin E and probucol against gentamicin-induced nephrotoxicity in rats. Pharmacol Res 1999; 40:183-187
29. Kavutcu M, Canbolat O, Ozturk S, et al: Reduced enzymatic antioxidant defense mechanism in kidney tissues from gentamicin-treated guinea pigs: Effects of vitamins E and C. Nephron 1996; 72:269-274
30. Ademuyiwa O, Ngaha EO, Ubah FO: Vitamin E and selenium in gentamicin nephrotoxicity. Hum Exp Toxicol 1990; 9:281-288
31. Walker PD, Barri Y, Shah SV: Oxidant mechanisms in gentamicin nephrotoxicity. Ren Fail 1999; 21:433-442
32. Ben Ismail TH, Ali BH, Bashir AA: Influence of iron, deferoxamine, and ascorbic acid on gentamicin-induced nephrotoxicity in rats. Gen Pharmacol 1994; 25:1249-1252
33. Davis BD: Mechanism of bactericidal action of aminoglycosides. Microbiol Rev 1987; 51:341-350
34. Leung JC, Marphis T, Craver RD, et al: Altered NMDA receptor expression in renal toxicity: Protection with a receptor antagonist. Kidney Int 2004; 66:167-176
35. Hatala R, Dinh T, Cook DJ: Once-daily aminoglycoside dosing in immunocompetent adults: A meta-analysis. Ann Intern Med 1996; 124:717-725
36. Munckhof WJ, Grayson ML, Turnidge JD: A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother 1996; 37:645-663
37. Galloe AM, Graudal N, Christensen HR, et al: Aminoglycosides: Single or multiple daily dosing? A meta-analysis on efficacy and safety. Eur J Clin Pharmacol 1995; 48:39-43
38. Barza M, Ioannidis JP, Cappelleri JC, et al: Single or multiple daily doses of aminoglycosides: A meta-analysis. BMJ 1996; 312:338-345
39. Ferriols-Lisart R, Alos-Alminana M: Effectiveness and safety of once-daily aminoglycosides: A meta-analysis. Am J Health Syst Pharm 1996; 53:1141-1150
40. Paterson DL, Robson JM, Wagener MM: Risk factors for toxicity in elderly patients given aminoglycosides once daily. J Gen Intern Med 1998; 13:735-739
41. Parker SE, Davey PG: Practicalities of once-daily aminoglycoside dosing. J Antimicrob Chemother 1993; 31:4-8
42. Prins JM, Weverling GJ, de Blok K, et al: Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy. Antimicrob Agents Chemother 1996; 40:2494-2499
43. McCormack JP, Jewesson PJ: A critical re-evaluation of the "therapeutic range" of aminoglycosides. Clin Infect Dis 1992; 14:320-339
44. Anaissie EJ, Vartivarian SE, Abi-Said D, et al: Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: A matched cohort study. Am J Med 1996; 101:170-176
45. Sabra R, Zeinoun N, Sharaf LH, et al: Role of humoral mediators in, and influence of a liposomal formulation on, acute amphotericin B nephrotoxicity. Pharmacol Toxicol 2001; 88:168-175
46. Sawaya BP, Briggs JP, Schnermann J: Amphotericin B nephrotoxicity: The adverse consequences of altered membrane properties. J Am Soc Nephrol 1995; 6:154-164
47. Luber AD, Maa L, Lam M, et al: Risk factors for amphotericin B-induced nephrotoxicity. J Antimicrob Chemother 1999; 43:267-271
48. Costa S, Nucci M: Can we decrease amphotericin nephrotoxicity? Curr Opin Crit Care 2001; 7:379-383
49. Bates DW, Su L, Yu DT, et al: Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001; 32:686-693
50. Llanos A, Cieza J, Bernardo J, et al: Effect of salt supplementation on amphotericin B nephrotoxicity. Kidney Int 1991; 40:302-308
51. Eriksson U, Seifert B, Schaffner A: Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: Randomised controlled trial. BMJ 2001; 322:579-582
52. Stevens DL: The role of vancomycin in the treatment paradigm. Clin Infect Dis. 2006; 42(Suppl 1):S51-S57
53. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 though June 2004. Am J Infect Dis 2004; 32:470-485
54. Rybak MJ, Albrecht LM, Boike SC, et al: Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 1990; 25:679-687
55. Hidayat LK, Hsu DI, Quist R, et al: High-dose vancomycin therapy for methicillinresistant Staphylococcus aureus infections: Efficacy and toxicity. Arch Intern Med 2006; 166:2138-2144
56. Barraclough K, Harris M, Montessori V, et al: An unusual case of acute kidney injury due to vancomycin lessons learnt from reliance on eGFR. Nephrol Dial Transplant 2007; 22:2391-2394
57. Buysen JG, Houthoff HJ, Krediet RT, et al: Acute interstitial nephritis: A clinical and morphological study in 27 patients. Nephrol Dial Transplant 1990; 5:94-99
58. Rossert J: Drug-induced acute interstitial nephritis. Kidney Int 2001; 60:804-817
59. Handa SP: Drug-induced acute interstitial nephritis: Report of 10 cases. CMAJ 1986; 135:1278-1281
60. Packer M, Lee WH, Medina N, et al: Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure. Ann Intern Med 1987; 106:346-354
61. Ljungman S, Kjekshus J, Swedberg K: Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). Am J Cardiol 1992; 70:479-487
62. Chittineni H, Miyawaki N, Gulipelli S, et al: Risk for acute renal failure in patients hospitalized for decompensated congestive heart failure. Am J Nephrol 2007; 27:55-62
63. Cruz CS, Cruz LS, Silva GR, et al: Incidence and predictors of development of acute renal failure related to treatment of congestive heart failure with ACE inhibitors. Nephron 2007; 105:c77-83
64. Packer M, Lee WH, Medina N, et al: Influence of renal function on the hemodynamic and clinical responses to long-term captopril therapy in severe chronic heart failure. Ann Intern Med 1986; 104:147-54
65. Whelton A: Nephrotoxicity of nonsteroidal anti-inflammatory drugs: Physiologic foundations and clinical implications. Am J Med 1999; 106:13S-24S
66. Hock R, Anderson RJ: Prevention of drug-induced nephrotoxicity in the intensive care unit. J Crit Care 1995; 10:33-43
67. Komhoff M, Grone HJ, Klein T, et al: Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: Implication for renal function. Am J Physiol 1997; 272(4 Pt 2):F460-8
68. Hao CM, Komhoff M, Guan Y, et al: Selective targeting of cyclooxygenase-2 reveals its role in renal medullary interstitial cell survival. Am J Physiol 1999; 277:F352-F359
69. Swan SK, Rudy DW, Lasseter KC, et al: Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann Intern Med 2000; 133:1-9
70. Perazella MA, Eras J: Are selective COX-2 inhibitors nephrotoxic? Am J Kidney Dis 2000; 35:937-940
71. Braden GL, O'Shea MH, Mulhern JG, et al: Acute renal failure and hyperkalemia associated with cyclooxygenase-2 inhibitors. Nephrol Dial Transplant 2004; 19:1149-1153
72. Friedrich JO, Adhikari N, Herridge MS, et al: Meta-analysis: Low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med 2005; 142:510-524
73. Kellum JA, M Decker J: Use of dopamine in acute renal failure: A meta-analysis. Crit Care Med 2001; 29:1526-1531
74. Marik PE: Low-dose dopamine: A systematic review. Intensive Care Med 2002; 28:877-883
75. Campistol JM, Sacks SH: Mechanisms of nephrotoxicity. Transplantation 2000; 69(Suppl 12):S5-S10
76. Lanese DM, Conger JD: Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles. J Clin Invest 1993; 91:2144-2149
77. Perico N, Ruggenenti P, Gaspari F, et al: Daily renal hypoperfusion induced by cyclosporine in patients with renal transplantation. Transplantation 1992; 54:56-60
78. Barros EJ, Boim MA, Ajzen H, et al: Glomerular hemodynamics and hormonal participation on cyclosporine nephrotoxicity. Kidney Int 1987; 32:19-25
79. Bobadilla NA, Tapia E, Franco M, et al: Role of nitric oxide in renal hemodynamic abnormalities of cyclosporin nephrotoxicity. Kidney Int 1994; 46:773-779
80. Kon V, Sugiura M, Inagami T, et al: Role of endothelin in cyclosporine-induced glomerular dysfunction. Kidney Int 1990; 37:1487-1491
81. Perico N, Benigni A, Bosco E, et al: Acute cyclosporine A nephrotoxicity in rats: Which role for renin-angiotensin system and glomerular prostaglandins? Clin Nephrol 1986; 25(Suppl 1):S83-S88
82. Gardner MP, Houghton DC, Andoh TF, et al: Clinically relevant doses and blood levels produce experimental cyclosporine nephrotoxicity when combined with nitric oxide inhibition. Transplantation 1996; 61:1506-1512
83. Ishani A, Erturk S, Hertz MI, et al: Predictors of renal function following lung or heart-lung transplantation. Kidney Int 2002; 61:2228-2234
84. Garlicki M, Czub P, Labus K, et al: Conversion from cyclosporine to tacrolimus improves renal function and lipid profile after cardiac transplantation. Ann Transplant 2006; 11:24-27
85. Klein IH, Abrahams A, van Ede T, et al: Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. Transplantation 2002; 73:732-736
86. Israni A, Brozena S, Pankewycz O, et al: Conversion to tacrolimus for the treatment of cyclosporine-associated nephrotoxicity in heart transplant recipients. Am J Kidney Dis 2002; 39:E16
87. Pratschke J, Neuhaus R, Tullius SG, et al: Treatment of cyclosporine-related adverse effects by conversion to tacrolimus after liver transplantation. Transplantation 1997; 64:938-940
88. Cantarovich D, Renou M, Megnigbeto A, et al: Switching from cyclosporine to tacrolimus in patients with chronic transplant dysfunction or cyclosporine-induced adverse events. Transplantation 2005; 79:72-78
89. Artz MA, Boots JM, Ligtenberg G, et al: Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function, and cardiovascular risk profile. Am J Transplant 2004; 4:937-945
90. English RF, Pophal SA, Bacanu SA, et al: Long-term comparison of tacrolimus- and cyclosporine-induced nephrotoxicity in pediatric heart-transplant recipients. Am J Transplant 2002; 2:769-773
91. Knight RJ, Kahan BD: The place of sirolimus in kidney transplantation: Can we reduce calcineurin inhibitor renal toxicity? Kidney Int 2006; 70:994-999
92. Kuypers DR, Neumayer HH, Fritsche L, et al: Calcium channel blockade and preservation of renal graft function in cyclosporine-treated recipients: A prospective randomized placebo-controlled 2-year study. Transplantation 2004; 78:1204-1211
93. Anderson W, Bethea W: Renal lesions following the administration of hypertonic solutions of sucrose. JAMA 1940; 114:1983-1987
94. Ahsan N, Palmer BF, Wheeler D, et al: Intravenous immunoglobulin-induced osmotic nephrosis. Arch Intern Med 1994; 154:1985-1987
95. Legendre C, Thervet E, Page B, et al: Hydroxyethylstarch and osmotic-nephrosis-like lesions in kidney transplantation. Lancet 1993; 342:248-249
96. Markowitz GS, Perazella MA: Drug-induced renal failure: A focus on tubulointerstitial disease. Clin Chim Acta 2005; 351:31-47
97. Schortgen F, Lacherade JC, Bruneel F, et al: Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: A multicentre randomised study. Lancet 2001; 357:911-916
98. Cittanova ML, Leblanc I, Legendre C, et al: Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients. Lancet 1996; 348:1620-1622
99. Daudon M, Estepa L, Viard JP, et al: Urinary stones in HIV-1-positive patients treated with indinavir. Lancet 1997; 349:1294-1295
100. James CW, Steinhaus MC, Szabo S, et al: Tenofovir-related nephrotoxicity: Case report and review of the literature. Pharmacotherapy 2004; 24:415-418
101. Gupta SK, Eustace JA, Winston JA, et al: Guidelines for the management of chronic kidney disease in HIV-infected patients: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005; 40:1559-1585
102. Daugas E, Rougier JP, Hill G: HAART-related nephropathies in HIV-infected patients. Kidney Int 2005; 67:393-403
103. Izzedine H, Launay-Vacher V, Deray G: Antiviral drug-induced nephrotoxicity. Am J Kidney Dis 2005; 45:804-817
104. Berns JS, Kasbekar N: Highly active anti-retroviral therapy and the kidney: An update on antiretroviral medications for nephrologists. Clin J Am Soc Nephrol 2006; 1:117-29
105. Hoste EA, Clermont G, Kersten A, et al: RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: A cohort analysis. Crit Care 2006; 10:R73
106. Burkhardt H, Hahn T, Gretz N, et al: Bedside estimation of the glomerular filtration rate in hospitalized elderly patients. Nephron 2005; 101:c1- c8
107. Horn E, Jacobi J: The critical care clinical pharmacist: Evolution of an essential team member. Crit Care Med 2006; 34(Suppl 3):S46-S51